SomaLogic Inc. announced its partnership with DNA Link, an innovator in and precision medicine, to offer the 7,000-plex SomaScan(R) platform to their customers. DNA Link will be the first SomaLogic authorized site in Korea. SomaLogic's 7,000-plex SomScan assay will significantly expand DNA Link's proteomics capabilities in its laboratory in Seoul, Korea.

DNA Link has been conducting genomics research from its labs for more than two decades with a focus on genetic epidemiology, drug development and medicine. Their multiomics offerings are available in Korea and across Asia. DNA Link joins Biostar in China, Molecular Genomics in Singapore and FonesLife in Japan as SomaLogic authorized sites in the APAC region.

For more than twenty years, SomaLogic has grown from its roots in the research lab to become a global leader in proteomics with technology that delivers the quality and quantity of biological insights life science researchers need - from lab to last mile.